REGISTERED NUMBER: 08252177 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

TTS PHARMA LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

P R Atherton

W C Blaney

REGISTERED OFFICE:

Liverpool Science Park

131 Mount Pleasant

Liverpool

Merseyside

L3 5TF

REGISTERED NUMBER:

08252177 (England and Wales)

ACCOUNTANTS:

Wallwork Nelson & Johnson

Chandler House

7 Ferry Road Office Park

Riversway

Preston

Lancashire

PR2 2YH

FIXED ASSETS

Tangible assets

4

4,801

6,522

Investments

5

1,215,168

1,215,168

1,219,969

1,221,690

CURRENT ASSETS

Stocks

18,847

18,070

Debtors

6

1,450,243

1,450,249

Cash at bank

2,667

162,690

1,471,757

1,631,009

CREDITORS

Amounts falling due within one year

7

646,246

683,880

NET CURRENT ASSETS

825,511

947,129

TOTAL ASSETS LESS CURRENT LIABILITIES

2,045,480

2,168,819

CREDITORS

Amounts falling due after more than one year

8

1,450,569

980,012

NET ASSETS

594,911

1,188,807

CAPITAL AND RESERVES

Called up share capital

6,466

6,466

Share premium

7,446,455

7,446,455

Retained earnings

(6,858,010

)

(6,264,114

)

594,911

1,188,807

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24 September 2025 and were signed on its behalf by:

P R Atherton - Director

1.	STATUTORY INFORMATION

TTS Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc

-

25% on cost

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 January 2024

13,443

Additions

656

At 31 December 2024

14,099

DEPRECIATION

At 1 January 2024

6,921

Charge for year

2,377

At 31 December 2024

9,298

NET BOOK VALUE

At 31 December 2024

4,801

At 31 December 2023

6,522

5.	FIXED ASSET INVESTMENTS

Shares in

group

Other

undertakings

investments

Totals

£

£

£

COST

At 1 January 2024

and 31 December 2024

213

1,214,955

1,215,168

NET BOOK VALUE

At 31 December 2024

213

1,214,955

1,215,168

At 31 December 2023

213

1,214,955

1,215,168

6.

DEBTORS

2024

2023

£

£

Amounts falling due within one year:

Trade debtors

225

-

Other debtors

62,101

128,666

62,326

128,666

Amounts falling due after more than one year:

Amounts owed by group undertakings

1,387,917

1,321,583

Aggregate amounts

1,450,243

1,450,249

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Bank loans and overdrafts

10,289

9,788

Trade creditors

386,323

208,722

Taxation and social security

231,467

385,466

Other creditors

18,167

79,904

646,246

683,880

8.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

2024

2023

£

£

Bank loans

8,778

19,315

Other creditors

1,441,791

960,697

1,450,569

980,012

9.	CONTINGENT LIABILITIES

On 19 April 2023, TTS received a claim filed in the Manchester Employment Tribunal by its former Chief Executive Officer, Mark Tucker, making various claims following his resignation with immediate effect on 11 November 2022. This case is ongoing and will likely continue into 2026. TTS believes that the claim has no merits and is in the process of vigorously and robustly defending it.

10.	POST BALANCE SHEET EVENTS

On 2 September 2025 the Company completed the acquisition of 100% of the issued share capital of Medisonal Limited.

11.	ULTIMATE CONTROLLING PARTY

The controlling party is P R Atherton.